Bone cancer is a broad term covering malignant tumours that either originate within the bone itself -- called primary bone cancer -- or spread to the bone from a cancer elsewhere in the body, called secondary or metastatic bone cancer. These are fundamentally different conditions with different causes, treatments, and prognoses, and understanding the distinction is the starting point for navigating a bone cancer diagnosis.
Primary bone cancers are rare, accounting for less than 1% of all cancers. They are, however, among the most common solid tumours of childhood and adolescence. Secondary bone cancer -- malignancy that has spread from breast, prostate, lung, kidney, or thyroid -- is significantly more common and represents the most frequent reason adults seek care for bone pain that turns out to be malignant.
The distinction between primary and secondary bone cancer shapes everything about management. This includes their investigation pathway, the treatment approaches, and likely outcomes.
Primary bone cancer arises from the cells that make up bone or cartilage tissue. These tumours are classified by their cell of origin: osteosarcoma from bone-forming cells, chondrosarcoma from cartilage-forming cells, Ewing sarcoma from a distinct neural crest cell, and several rarer types. Because they arise within the bone itself, they behave according to the biology of bone tissue and are treated as a distinct group of cancers.
Secondary bone cancer, by contrast, is not really a bone cancer at all -- it is the same cancer as the primary site, just located in bone. Breast cancer cells that have spread to the vertebrae are still breast cancer cells, responsive to breast cancer treatments. The bone is simply where they have come to rest. Secondary bone cancer is managed primarily by treating the underlying primary cancer alongside bone-specific treatments to prevent fractures and control pain.
There are several distinct types of primary bone cancer, classified by the cell type from which they originate. Each has a characteristic age of onset, location preference, biological behaviour, and treatment approach.
Osteosarcoma arises from osteoblasts, the cells responsible for forming new bone tissue. It typically develops during periods of rapid bone growth, which is why it most commonly affects teenagers and young adults between 10 and 30 years, with a peak in adolescence.
Osteosarcoma is aggressive and can spread to the lungs relatively early. Treatment involves neoadjuvant chemotherapy (before surgery to shrink the tumor and treat microscopic spread), followed by limb-salvage surgery or, in selected cases, amputation, followed by adjuvant chemotherapy. The response of the tumor to neoadjuvant chemotherapy -- assessed by the pathologist in the resected specimen -- is one of the most important prognostic factors.
Ewing sarcoma is the second most common primary bone cancer in children and adolescents. It commonly affects the shaft of long bones, as well as flat bones including the pelvis, ribs, scapula, and vertebrae. Fever, weight loss, and systemic symptoms are more prominent with Ewing sarcoma than with other primary bone tumours. Ewing sarcoma is highly radiosensitive, and radiotherapy plays a role alongside chemotherapy and surgery. With multimodal treatment, localised disease has a 5-year survival rate of approximately 70-80%.
Chondrosarcoma is the most common primary bone cancer in adults, typically arising after the age of 40. It develops from cartilage cells and may arise de novo in bone or, less commonly, from a pre-existing benign cartilage lesion. The pelvis, femur, humerus, and ribs are the most common sites. It is one of the few solid tumors that is almost entirely resistant to both chemotherapy and radiotherapy -- its treatment is surgical, and the outcome depends almost entirely on achieving wide, clear surgical margins.
Giant cell tumor of bone is a benign-aggressive tumor arising most commonly around the knee (distal femur, proximal tibia) and the distal radius in young adults, typically between 20 and 40 years. While not a cancer in the traditional sense, it can be locally destructive, erode through cortex, and in a small proportion of cases (approximately 2-5%) metastasise to the lungs.
Secondary bone cancer occurs when malignant cells from a primary tumor elsewhere in the body -- most commonly breast, prostate, lung, kidney, or thyroid -- travel through the bloodstream and establish new tumor deposits in the bone. Secondary bone cancer causes pain, reduces bone strength, and can compress the spinal cord.
The symptoms of bone cancer depend on the tumour type, location, and stage. Some symptoms are common to all types; others are specific to particular tumors or locations.
The cause of most primary bone cancers is not fully understood. Unlike many adult cancers, lifestyle factors play little role. The following conditions and factors are associated with increased risk:
Genetic and hereditary conditions
Prior conditions and exposures
Non-modifiable factors
Bone cancer diagnosis requires a combination of clinical assessment, imaging, and histological confirmation by biopsy. The sequence and completeness of this process directly affects treatment planning and outcome. One of the most common and serious errors in bone cancer management is performing a biopsy before adequate imaging, or performing it in a way that compromises subsequent surgery.
The correct diagnostic sequence is: clinical assessment and plain X-ray first, followed by advanced imaging (MRI for local extent, CT for pulmonary metastases), and only then a biopsy -- ideally performed by or in close consultation with the surgeon who will perform the definitive resection.
